デフォルト表紙
市場調査レポート
商品コード
966769

クラミジア感染症:2030年までの疫学予測

Chlamydia - Epidemiology Insight - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円
クラミジア感染症:2030年までの疫学予測
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、米国、ドイツ、フランス、イタリア、スペイン、英国、日本の主要7ヶ国のクラミジア感染症の疫学と関連市場について調査したもので、疾病の背景と概要、疫学と患者数、現在の治療法、主な専門家の見解、アンメットニーズなどの情報を提供しています。

目次

第1章 主な調査結果

第2章 エグゼクティブサマリー

第3章 疾患の背景と概要

  • イントロダクション
  • 兆候と症状
  • 病態生理学
  • 危険因子
  • 診断

第4章 ペイシェントジャーニー

第5章 疫学と患者数

  • 主な調査結果
  • 前提と根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 主要7ヶ国における疫学シナリオ
  • 米国
  • 欧州5ヶ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第6章 治療アルゴリズム、現在の治療と医療

  • 治療と管理
  • 治療アルゴリズム

第7章 主な専門家の見解

第8章 アンメットニーズ

第9章 付録

  • 参考文献
  • レポートの調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Chlamydia Epidemiology in 7MM (2017-2030)
  • Table 2: Chlamydia Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: Chlamydia Epidemiology in the United States (2017-2030)
  • Table 4: Chlamydia Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: Chlamydia Epidemiology in Germany (2017-2030)
  • Table 6: Chlamydia Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: Chlamydia Epidemiology in France (2017-2030)
  • Table 8: Chlamydia Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: Chlamydia Epidemiology in Italy (2017-2030)
  • Table 10: Chlamydia Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: Chlamydia Epidemiology in Spain (2017-2030)
  • Table 12: Chlamydia Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: Chlamydia Epidemiology in the United Kingdom (2017-2030)
  • Table 14: Chlamydia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: Chlamydia Epidemiology in Japan (2017-2030)
  • Table 16: Chlamydia Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: Chlamydia Epidemiology in 7MM (2017-2030)
  • Figure 2: Chlamydia Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: Chlamydia Epidemiology in the United States (2017-2030)
  • Figure 4: Chlamydia Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: Chlamydia Epidemiology in Germany (2017-2030)
  • Figure 6: Chlamydia Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: Chlamydia Epidemiology in France (2017-2030)
  • Figure 8: Chlamydia Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: Chlamydia Epidemiology in Italy (2017-2030)
  • Figure 10: Chlamydia Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: Chlamydia Epidemiology in Spain (2017-2030)
  • Figure 12: Chlamydia Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: Chlamydia Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: Chlamydia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: Chlamydia Epidemiology in Japan (2017-2030)
  • Figure 16: Chlamydia Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1044

DelveInsight's 'Chlamydia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chlamydia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Chlamydia Understanding

The DelveInsight Chlamydia epidemiology report gives a thorough understanding of the Chlamydia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Chlamydia in the US, Europe, and Japan. The report covers the detailed information of the Chlamydia epidemiology scenario in seven major countries (US, EU5, and Japan).

Chlamydia Epidemiology Perspective by DelveInsight

The Chlamydia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chlamydia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chlamydia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chlamydia Detailed Epidemiology Segmentation

The Chlamydia epidemiology covered in the report provides historical as well as forecasted Chlamydia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Chlamydia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Chlamydia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Chlamydia Epidemiology Report and Model provide an overview of the risk factors and global trends of Chlamydia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Chlamydia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Chlamydia
  • The report provides the segmentation of the Chlamydia epidemiology

Report Highlights:

  • 11-Year Forecast of Chlamydia epidemiology
  • 7MM Coverage
  • Total Cases of Chlamydia
  • Total Cases of Chlamydia according to segmentation
  • Diagnosed cases of Chlamydia

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chlamydia ?
  • What are the key findings pertaining to the Chlamydia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Chlamydia across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Chlamydia ?
  • What are the currently available treatments of Chlamydia ?

Reasons to buy:

  • The Chlamydia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Chlamydia market
  • Quantify patient populations in the global Chlamydia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chlamydia therapeutics in each of the markets covered
  • Understand the magnitude of Chlamydia population by its epidemiology
  • The Chlamydia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of Chlamydia

3. Chlamydia : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. Chlamydia Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. Chlamydia Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. Chlamydia Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. Chlamydia Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. Chlamydia Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. Chlamydia Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. Chlamydia Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. Chlamydia Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. Chlamydia Treatment and Management
  • 6.2. Chlamydia Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report